In cases of rare kidney cancers, such as TFEB rearranged RCC, the small number of published cases and the limited knowledge of the molecular landscape and the genetic profile of the disease has limited the possibility of developing targeted drugs and selective compounds. The gene discussed is TFEB; the disease is renal cell carcinoma.